Business● LowJun 24 · Jun 24, 2026, 10:52 AM
Lilly inks R&D deal worth up to $1.9B with China’s Abbisko
GlobeAlert Desk · curated from Seeking Alpha Tech
Lilly has finalized a research and development agreement with China's Abbisko, potentially valued at up to $1.9 billion. This represents a substantial collaboration in the pharmaceutical industry.
GlobeAlert aggregates and classifies open sources; the story above belongs to its publisher. Summaries are machine-generated from the source text. How we score stories.
GlobeAlert context
What the desk knows about this story
Threat level
1 Low
Scored from severity, scale, escalation potential and source agreement. Below the alert threshold.
Sources
1 publisher
Single-source so far. Treat details as unconfirmed until more publishers report.
Category
Business
Not flagged as developing.
More in Business
Business23m agoSK Telecom GAAP EPS of $1917.00, revenue of $4497.3BSeeking Alpha TechBusiness31m agoED raids in Odisha, Bengal in investment 'fraud' case'The HinduBusiness40m agoAudioCodes Non-GAAP EPS of $0.16 in-line, revenue of $64.1M beats by $0.7MSeeking Alpha TechBusiness42m agoAtriCure projects 2026 adjusted EBITDA of $91M-$94M as it targets BoxX-NoAF enrollment completion by year-endSeeking Alpha Tech